Cargando…
Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin
Previous work has shown that cannabinoids increase feeding, while cholecystokinin (CCK) has an anorexigenic effect on food intake. Receptors for these hormones are located on cell bodies of vagal afferent nerves in the nodose ganglia. An interaction between CCK and endocannabinoid receptors has been...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278814/ https://www.ncbi.nlm.nih.gov/pubmed/30512249 http://dx.doi.org/10.14814/phy2.13927 |
_version_ | 1783378436186701824 |
---|---|
author | Johnston, Juliane R. Freeman, Kimberly G. Edwards, Gaylen L. |
author_facet | Johnston, Juliane R. Freeman, Kimberly G. Edwards, Gaylen L. |
author_sort | Johnston, Juliane R. |
collection | PubMed |
description | Previous work has shown that cannabinoids increase feeding, while cholecystokinin (CCK) has an anorexigenic effect on food intake. Receptors for these hormones are located on cell bodies of vagal afferent nerves in the nodose ganglia. An interaction between CCK and endocannabinoid receptors has been suggested. The purpose of these studies is to explore the effect of pretreatment with a cannabinoid agonist, CP 55,940, on nodose neuron activation by CCK. To determine the effect of CP 55,940 and CCK on neuron activation, rats were anesthetized and nodose ganglia were excised. The neurons were dissociated and placed in culture on coverslips. The cells were treated with media; CP 55,940; CCK; CP 55,940 followed by CCK; or AM 251, a CB1 receptor antagonist, and CP 55,940 followed by CCK. Immunohistochemistry was performed to stain the cells for cFos as a measure of cell activation. Neurons were identified using neurofilament immunoreactivity. The neurons on each slip were counted using fluorescence imaging, and the number of neurons that were cFos positive was counted in order to calculate the percentage of activated neurons per coverslip. Pretreatment with CP 55,940 decreased the percentage of neurons expressing cFos‐immunoreactivity in response to CCK. This observation suggests that cannabinoids inhibit CCK activation of nodose ganglion neurons. |
format | Online Article Text |
id | pubmed-6278814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62788142018-12-10 Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin Johnston, Juliane R. Freeman, Kimberly G. Edwards, Gaylen L. Physiol Rep Original Research Previous work has shown that cannabinoids increase feeding, while cholecystokinin (CCK) has an anorexigenic effect on food intake. Receptors for these hormones are located on cell bodies of vagal afferent nerves in the nodose ganglia. An interaction between CCK and endocannabinoid receptors has been suggested. The purpose of these studies is to explore the effect of pretreatment with a cannabinoid agonist, CP 55,940, on nodose neuron activation by CCK. To determine the effect of CP 55,940 and CCK on neuron activation, rats were anesthetized and nodose ganglia were excised. The neurons were dissociated and placed in culture on coverslips. The cells were treated with media; CP 55,940; CCK; CP 55,940 followed by CCK; or AM 251, a CB1 receptor antagonist, and CP 55,940 followed by CCK. Immunohistochemistry was performed to stain the cells for cFos as a measure of cell activation. Neurons were identified using neurofilament immunoreactivity. The neurons on each slip were counted using fluorescence imaging, and the number of neurons that were cFos positive was counted in order to calculate the percentage of activated neurons per coverslip. Pretreatment with CP 55,940 decreased the percentage of neurons expressing cFos‐immunoreactivity in response to CCK. This observation suggests that cannabinoids inhibit CCK activation of nodose ganglion neurons. John Wiley and Sons Inc. 2018-12-04 /pmc/articles/PMC6278814/ /pubmed/30512249 http://dx.doi.org/10.14814/phy2.13927 Text en © 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Johnston, Juliane R. Freeman, Kimberly G. Edwards, Gaylen L. Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin |
title | Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin |
title_full | Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin |
title_fullStr | Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin |
title_full_unstemmed | Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin |
title_short | Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin |
title_sort | activity in nodose ganglia neurons after treatment with cp 55,940 and cholecystokinin |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278814/ https://www.ncbi.nlm.nih.gov/pubmed/30512249 http://dx.doi.org/10.14814/phy2.13927 |
work_keys_str_mv | AT johnstonjulianer activityinnodoseganglianeuronsaftertreatmentwithcp55940andcholecystokinin AT freemankimberlyg activityinnodoseganglianeuronsaftertreatmentwithcp55940andcholecystokinin AT edwardsgaylenl activityinnodoseganglianeuronsaftertreatmentwithcp55940andcholecystokinin |